MY151439A - Medium-chain length fatty acids and glycerides as nephroprotection agents - Google Patents
Medium-chain length fatty acids and glycerides as nephroprotection agentsInfo
- Publication number
- MY151439A MY151439A MYPI2010001861A MYPI20101861A MY151439A MY 151439 A MY151439 A MY 151439A MY PI2010001861 A MYPI2010001861 A MY PI2010001861A MY PI20101861 A MYPI20101861 A MY PI20101861A MY 151439 A MY151439 A MY 151439A
- Authority
- MY
- Malaysia
- Prior art keywords
- nephroprotection
- agents
- medium
- fatty acids
- chain length
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- 125000005456 glyceride group Chemical group 0.000 title 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 abstract 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000005639 Lauric acid Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 230000001434 glomerular Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000013059 nephrectomy Methods 0.000 abstract 1
- 229960002446 octanoic acid Drugs 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98509407P | 2007-11-02 | 2007-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY151439A true MY151439A (en) | 2014-05-30 |
Family
ID=40590499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010001861A MY151439A (en) | 2007-11-02 | 2008-11-03 | Medium-chain length fatty acids and glycerides as nephroprotection agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9532962B2 (enExample) |
| EP (1) | EP2299998B1 (enExample) |
| JP (1) | JP5575655B2 (enExample) |
| KR (1) | KR101601987B1 (enExample) |
| CN (1) | CN101878028A (enExample) |
| AU (1) | AU2008318196B2 (enExample) |
| BR (1) | BRPI0818310A8 (enExample) |
| CA (1) | CA2704286C (enExample) |
| DK (1) | DK2299998T3 (enExample) |
| ES (1) | ES2664594T3 (enExample) |
| IL (1) | IL205362A (enExample) |
| MX (1) | MX338513B (enExample) |
| MY (1) | MY151439A (enExample) |
| NO (1) | NO2299998T3 (enExample) |
| NZ (1) | NZ584981A (enExample) |
| PT (1) | PT2299998T (enExample) |
| RU (1) | RU2519215C2 (enExample) |
| WO (1) | WO2009055933A1 (enExample) |
| ZA (1) | ZA201003030B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2427416E (pt) | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Compostos aromáticos substituídos e seus usos farmacêuticos |
| JP5706142B2 (ja) * | 2010-04-28 | 2015-04-22 | 株式会社ファンケル | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤 |
| EA035494B1 (ru) * | 2010-10-27 | 2020-06-25 | Прометик Фарма Смт Лимитед | Способ и применение композиции для ингибирования миграции клеток опухоли и образования метастазов |
| WO2013031729A1 (ja) | 2011-08-26 | 2013-03-07 | 国立大学法人大阪大学 | 糖尿病性心血管合併症の予防・治療剤 |
| KR20130023583A (ko) * | 2011-08-29 | 2013-03-08 | 아주대학교산학협력단 | 파골세포 형성 억제 효과가 있는 카프르산 및 이를 포함하는 약학적 조성물 |
| US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
| WO2017074266A1 (en) * | 2015-10-30 | 2017-05-04 | National University Of Singapore | Androgen biosynthesis inhibitor |
| CN105559071A (zh) * | 2016-01-12 | 2016-05-11 | 刘保惠 | 一种适用于肾病的特殊医学用途配方食品及其制备方法 |
| JP2017214342A (ja) * | 2016-06-02 | 2017-12-07 | 日清オイリオグループ株式会社 | 排尿障害の予防用又は改善用組成物 |
| CN110300581B (zh) | 2016-06-08 | 2023-09-08 | 善睿圣医药保健股份有限公司 | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 |
| WO2018115953A1 (en) * | 2016-12-21 | 2018-06-28 | Prometic Pharma Smt Limited | Methods and compositions for preventing or minimizing epithelial-mesenchymal transition |
| WO2019082912A1 (ja) * | 2017-10-27 | 2019-05-02 | 学校法人北里研究所 | 慢性腎臓病の予防又は治療剤 |
| WO2019155336A1 (en) * | 2018-02-08 | 2019-08-15 | Societe Des Produits Nestle S.A. | Mct-based nutrition blend for providing health benefits in companion animals |
| SG11202103011YA (en) | 2018-10-11 | 2021-04-29 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| CN109602012A (zh) * | 2018-12-11 | 2019-04-12 | 李卫平 | 一种功能性低蛋白能量米及其制备方法 |
| CN111184728B (zh) * | 2020-02-20 | 2023-04-04 | 上海市儿童医院 | 海藻糖在肾病综合征中的应用 |
| AU2023292465A1 (en) * | 2022-06-15 | 2024-12-12 | Hill's Pet Nutrition, Inc. | Pet food compositions |
| CN118592613B (zh) * | 2024-08-05 | 2025-01-07 | 杭州康源食品科技有限公司 | 中链脂肪酸混合结构脂在改善膳食诱导的糖脂代谢紊乱中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4602040A (en) | 1983-04-18 | 1986-07-22 | Warner-Lambert Company | Meclofenamic acid topical pharmaceutical composition |
| US4737384A (en) * | 1985-11-01 | 1988-04-12 | Allied Corporation | Deposition of thin films using supercritical fluids |
| CA2107581A1 (en) * | 1992-02-07 | 1993-08-08 | Kiyoshi Sugiyama | Side-effect alleviant |
| US6689700B1 (en) * | 1999-11-02 | 2004-02-10 | University Of Massachusetts | Chemical fluid deposition method for the formation of metal and metal alloy films on patterned and unpatterned substrates |
| CN100348183C (zh) | 2000-06-20 | 2007-11-14 | 营养科学公司 | 可用作抗微生物剂的中链脂肪酸 |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| BR0208984A (pt) * | 2001-04-18 | 2004-06-29 | Prometic Biosciences Inc | ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos |
| CN1827766B (zh) * | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
| RU2213570C2 (ru) * | 2001-08-22 | 2003-10-10 | Санкт-Петербургская Государственная Химико-Фармацевтическая Академия | ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ |
| US7030168B2 (en) * | 2001-12-31 | 2006-04-18 | Advanced Technology Materials, Inc. | Supercritical fluid-assisted deposition of materials on semiconductor substrates |
| US20040052836A1 (en) * | 2002-09-13 | 2004-03-18 | Li Luk Chiu | Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life |
| US9682054B2 (en) * | 2003-02-07 | 2017-06-20 | Prometic Pharma Smt Limited | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
| AU2004261461B2 (en) * | 2003-07-25 | 2008-12-18 | Prometic Pharma Smt Limited | Preparation of metal salts of medium-chain fatty acids |
| EP1940379A4 (en) * | 2005-09-30 | 2009-05-13 | Jackson H M Found Military Med | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |
-
2008
- 2008-11-03 MX MX2010004856A patent/MX338513B/es active IP Right Grant
- 2008-11-03 JP JP2010532389A patent/JP5575655B2/ja not_active Expired - Fee Related
- 2008-11-03 KR KR1020107012064A patent/KR101601987B1/ko not_active Expired - Fee Related
- 2008-11-03 MY MYPI2010001861A patent/MY151439A/en unknown
- 2008-11-03 US US12/740,700 patent/US9532962B2/en not_active Expired - Fee Related
- 2008-11-03 CA CA2704286A patent/CA2704286C/en not_active Expired - Fee Related
- 2008-11-03 BR BRPI0818310A patent/BRPI0818310A8/pt not_active IP Right Cessation
- 2008-11-03 WO PCT/CA2008/001930 patent/WO2009055933A1/en not_active Ceased
- 2008-11-03 PT PT88451224T patent/PT2299998T/pt unknown
- 2008-11-03 AU AU2008318196A patent/AU2008318196B2/en not_active Ceased
- 2008-11-03 RU RU2010122302/15A patent/RU2519215C2/ru active
- 2008-11-03 CN CN200880113724XA patent/CN101878028A/zh active Pending
- 2008-11-03 NO NO08845122A patent/NO2299998T3/no unknown
- 2008-11-03 NZ NZ584981A patent/NZ584981A/en not_active IP Right Cessation
- 2008-11-03 EP EP08845122.4A patent/EP2299998B1/en not_active Not-in-force
- 2008-11-03 ES ES08845122.4T patent/ES2664594T3/es active Active
- 2008-11-03 DK DK08845122.4T patent/DK2299998T3/en active
-
2010
- 2010-04-26 IL IL205362A patent/IL205362A/en active IP Right Grant
- 2010-04-30 ZA ZA2010/03030A patent/ZA201003030B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2299998B1 (en) | 2018-01-03 |
| IL205362A0 (en) | 2010-12-30 |
| MX338513B (es) | 2016-04-20 |
| KR20100106958A (ko) | 2010-10-04 |
| PT2299998T (pt) | 2018-04-02 |
| EP2299998A4 (en) | 2011-03-30 |
| RU2010122302A (ru) | 2011-12-10 |
| NO2299998T3 (enExample) | 2018-06-02 |
| ES2664594T3 (es) | 2018-04-20 |
| CN101878028A (zh) | 2010-11-03 |
| US9532962B2 (en) | 2017-01-03 |
| WO2009055933A1 (en) | 2009-05-07 |
| US20100286269A1 (en) | 2010-11-11 |
| CA2704286A1 (en) | 2009-05-07 |
| DK2299998T3 (en) | 2018-03-26 |
| EP2299998A1 (en) | 2011-03-30 |
| IL205362A (en) | 2015-01-29 |
| KR101601987B1 (ko) | 2016-03-09 |
| RU2519215C2 (ru) | 2014-06-10 |
| AU2008318196B2 (en) | 2014-04-10 |
| ZA201003030B (en) | 2011-02-23 |
| MX2010004856A (es) | 2010-06-30 |
| CA2704286C (en) | 2016-08-23 |
| AU2008318196A1 (en) | 2009-05-07 |
| JP2011502174A (ja) | 2011-01-20 |
| BRPI0818310A8 (pt) | 2017-12-26 |
| NZ584981A (en) | 2012-05-25 |
| JP5575655B2 (ja) | 2014-08-20 |
| BRPI0818310A2 (pt) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY151439A (en) | Medium-chain length fatty acids and glycerides as nephroprotection agents | |
| WO2007073486A3 (en) | Methods and compositions for delivering active agents with enhanced pharmacological properties | |
| EP2671584A3 (en) | Compositions and methods for treating disorders associated with salt or fluid retention | |
| WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
| WO2012019188A3 (en) | Methods and compositions for the inhibition of fructokinase | |
| CL2012002317A1 (es) | Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras. | |
| EP4678242A3 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX381737B (es) | Agonistas de guanilato ciclasa útiles en la preparación de medicamentos para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. | |
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
| WO2009063222A3 (en) | Solid compositions | |
| EP2355658A4 (en) | NEW LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | |
| EP2211913A4 (en) | SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS | |
| WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
| EP2638903A4 (en) | SUPPRESSOR FOR INCREASING THE BLOOD SUGAR MIRROR | |
| JP2010222367A5 (enExample) | ||
| IL193099A (en) | Use of ferric citrate-containing preparations in the preparation of chronic kidney disease drugs | |
| TR201901110T4 (tr) | Empagliflozinin terapötik kullanımları. | |
| WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
| CL2012000333A1 (es) | Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico. | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
| MX385881B (es) | Forma de dosificacion de alivio prolongado | |
| WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
| EP2167071A4 (en) | BACLOFEN SOLUTION FOR LOW VOLUME THERAPEUTIC DELIVERY |